Partial
Not Aligned
Patient Risk:
Moderate
Summary
Many generic claims about pain/fever and ibuprofen adverse effects partially align with NSAID-associated warnings, but the response contains substantial unsupported/non-label-specific statements (e.g., paracetamol/acetaminophen and chlorzoxazone uses and risks) that are not supported by the provided CALDOLOR (ibuprofen injection) FDA label excerpts; it also omits key CALDOLOR-specific administration instructions and safety monitoring elements (hydration/infusion dilution and BP monitoring).
Category Scores
Accurate Statements
Ibuprofen is used to reduce pain and inflammation.
Label indicates CALDOLOR is indicated for management of mild to moderate pain and moderate to severe pain as adjunct to opioid analgesics (and reduction of fever); inflammation is not explicitly stated in the provided sections.
Ibuprofen reduces fever.
1 INDICATIONS AND USAGE: CALDOLOR indicated for reduction of fever.
Ibuprofen helps with inflammation and pain.
Label supports pain management for CALDOLOR; inflammation is not explicitly stated in the provided sections.
Ibuprofen can cause stomach irritation or heartburn and nausea.
5.2 GI risk section describes serious GI adverse events; label excerpt does not specifically list heartburn/nausea, but GI adverse events are discussed as frequent.
Ibuprofen can raise blood pressure in some people.
5.4 Hypertension: NSAIDs can lead to new onset of hypertension or worsening of preexisting hypertension.
Extra caution is needed for people with a history of stomach ulcers or GI bleeding because of ibuprofen.
5.2 GI section: patients with prior history of peptic ulcer disease and/or GI bleeding have greater than 10-fold increased risk.
Severe stomach pain, vomiting blood, passing black stools, trouble breathing, swelling, fainting, severe dizziness, or yellowing of the skin/eyes require urgent medical help.
5.2 states serious GI events can occur and recommends remain alert for signs/symptoms and strategies to minimize GI risk; the listed symptom set includes elements not specifically contained in the provided CALDOLOR excerpts.
Unsupported Statements
Paracetamol (acetaminophen) is used to relieve mild to moderate pain.
Provided label excerpts are for CALDOLOR (ibuprofen injection) only; no acetaminophen/ paracetamol labeling support provided.
Paracetamol reduces fever.
No acetaminophen/paracetamol labeling support provided in the CALDOLOR excerpts.
Chlorzoxazone is a muscle relaxant.
No chlorzoxazone labeling support provided; CALDOLOR label is for ibuprofen injection.
Chlorzoxazone is used to relieve muscle spasms and muscle pain.
No chlorzoxazone labeling support provided.
A tablet containing ibuprofen, paracetamol, and chlorzoxazone is generally used when treatment is needed for general pain/fever and muscle spasm.
Provided FDA labeling excerpts are for CALDOLOR (ibuprofen injection) and do not describe combination tablets with paracetamol/chlorzoxazone.
Combinations are used when pain is both painful/inflammatory and related to muscle tension or spasm.
Combination product rationale not supported by provided CALDOLOR labeling excerpts.
Doctors commonly use this kind of combination for musculoskeletal pain that includes muscle spasm.
No statement in the provided CALDOLOR label excerpts about combination use or prescribing practices.
The combination is commonly used for acute back or neck pain with muscle spasm.
No such indication statements in provided CALDOLOR excerpts.
The combination is commonly used for muscle strains and sprains.
No such indication statements in provided CALDOLOR excerpts.
The combination is commonly used for other short-term muscle-related aches where relaxation of spasm is needed.
No such indication statements in provided CALDOLOR excerpts.
Ibuprofen increases the risk of stomach ulcers or bleeding, especially with higher doses or long use.
Label excerpts support serious GI events and increased risk in higher doses/with duration for CV thrombotic events; GI section excerpt supports increased risk with prior ulcer/GI bleed, but the specific “especially with higher doses or long use” phrasing is not explicitly supported in the provided GI excerpt.
Ibuprofen can cause kidney strain in some people.
Renal adverse reaction minimization (hydration) is mentioned, but “kidney strain” is not directly stated in provided excerpts.
Chlorzoxazone can cause drowsiness or dizziness.
No chlorzoxazone labeling support provided.
Chlorzoxazone can cause possible stomach upset.
No chlorzoxazone labeling support provided.
Extra caution is needed for people with significant liver disease or heavy alcohol use because of paracetamol.
No paracetamol/acetaminophen labeling support provided.
Extra caution is needed for people with kidney problems because of ibuprofen.
The provided label excerpt includes hydration to reduce renal adverse reactions, but does not provide this specific “kidney problems” caution statement.
Extra caution is needed for people who need to avoid drowsiness because chlorzoxazone can impair alertness.
No chlorzoxazone labeling support provided.
Paracetamol should not be doubled up because many cold/flu medicines already contain it.
No paracetamol/acetaminophen-specific guidance is present in provided CALDOLOR excerpts.
Contradictions
Low
AI Statement
A tablet containing ibuprofen, paracetamol, and chlorzoxazone is generally used when treatment is needed for general pain/fever and muscle spasm.
Label Reference
Provided CALDOLOR label indicates CALDOLOR injection for pain and fever; it does not support use of a combination tablet with paracetamol/chlorzoxazone.
Important Omissions
For CALDOLOR injection, MUST be diluted prior to administration.
Importance:
Moderate
To reduce risk of renal adverse reactions, patients must be well hydrated prior to administration of CALDOLOR.
Importance:
Moderate
Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
Importance:
Moderate
Monitor blood pressure during initiation of NSAID treatment (hypertension warning).
Importance:
Moderate
Contraindications specific to CALDOLOR: hypersensitivity to ibuprofen/components; history of asthma/urticaria/allergic-type reactions to aspirin/other NSAIDs; CABG surgery setting.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response includes some correct, general NSAID safety themes (GI seriousness, MI/stroke boxed warning indirectly via GI/CV risk awareness, and hypertension) but also introduces multiple unsupported claims about non-ibuprofen components and fails to include several key CALDOLOR-specific administration and contraindication elements (dilution, hydration, CABG and NSAID hypersensitivity history), which could mislead safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Substantial unsupported content unrelated to CALDOLOR (paracetamol/chlorzoxazone and combination tablet indications/risks) plus material omissions of CALDOLOR-specific contraindications and administration instructions (dilution/hydration) and monitoring (BP).
Suggested Improvement
Limit claims strictly to CALDOLOR (ibuprofen injection) indications, contraindications, boxed warning risks, and CALDOLOR-specific dosing/administration (lowest effective dose/shortest duration; hydration prior to administration; dilution requirement) and include required monitoring guidance (e.g., BP monitoring during initiation). Remove or clearly separate non-ibuprofen component claims not present in the supplied CALDOLOR labeling.